Which Infusions Require Baseline ECG and Contraindications
Baseline ECG is mandatory before administering QT-prolonging chemotherapy agents (particularly arsenic trioxide, anthracyclines, tyrosine kinase inhibitors, and histone deacetylase inhibitors), antiarrhythmic drugs (especially sotalol and dofetilide), and 5-fluorouracil, with treatment contraindicated if QTc >500 ms or baseline QTc prolongation >60 ms from prior measurements.
Medications Requiring Baseline ECG
Chemotherapy Agents - Highest Priority
QT-Prolonging Cancer Drugs 1, 2, 1:
- Arsenic trioxide (highest risk: 35% develop QTc >60 ms, 25-60% develop QTc >500 ms, 2.5% develop torsades de pointes) - requires weekly ECG monitoring
- Anthracyclines (doxorubicin): ECG required before initiation, though primarily for detecting acute ischemia and arrhythmias during infusion rather than QT prolongation 3, 1
- Tyrosine kinase inhibitors: Vandetanib (36 ms average QT prolongation), nilotinib, dasatinib, sunitinib, lapatinib
- Histone deacetylase inhibitors: Romidepsin, vorinostat
- 5-Fluorouracil: Cardiac monitoring during infusion is essential, especially the first dose, as 90% of lethal arrhythmias occur during first administration 3
Antiarrhythmic Drugs
Mandatory ECG requirement 4:
- Sotalol (Class III antiarrhythmic)
- Dofetilide (Class III antiarrhythmic)
Other High-Risk Medications
Methadone 4: ECG should be performed after each dose change due to high QT-prolonging risk
ECG Findings That Contraindicate Infusion
Absolute Contraindications 1, 2, 1:
- QTc >500 ms - treatment should be temporarily interrupted
- QTc prolongation >60 ms from baseline - treatment should be temporarily interrupted
- Active dysrhythmias (particularly torsades de pointes or ventricular tachycardia)
Relative Contraindications Requiring Intervention First:
- Baseline QTc >450 ms (men) or >460 ms (women) - upper limit of normal; proceed with extreme caution and frequent monitoring 1, 2, 1
- Bradycardia - increases torsades risk
- Conduction abnormalities suggesting underlying cardiac disease
- ST-T wave changes suggesting active ischemia (particularly for 5-fluorouracil) 3
Management Algorithm When Baseline ECG is Abnormal
Step 1: Identify and correct predisposing factors 1, 2, 1:
- Correct hypokalemia (target K+ 4.5-5.0 mmol/L)
- Correct hypomagnesemia
- Correct hypocalcemia
- Review and discontinue other QT-prolonging medications (check www.crediblemeds.org)
- Assess renal function (many QT-prolonging drugs accumulate in renal disease) 4
Step 2: Risk stratification:
- If QTc <500 ms and <60 ms increase from baseline after correction: May proceed with increased monitoring frequency
- If QTc ≥500 ms or ≥60 ms increase: Temporarily interrupt treatment, correct factors, recheck ECG
- Once QTc normalizes: Resume at reduced dose 1, 2, 1
Step 3: Monitoring schedule for high-risk agents 1, 2, 1:
- Baseline ECG
- 7-15 days after initiation or dose change
- Monthly during first 3 months
- Periodically thereafter based on drug and patient status
- Weekly for arsenic trioxide
- More frequently if patient develops diarrhea (increases electrolyte abnormalities)
Special Considerations
5-Fluorouracil 3:
- Causes coronary spasm and ischemia independent of underlying coronary disease
- Immediate discontinuation required if symptoms or ECG changes of ischemia occur during infusion
- Never rechallenge - sensitizes patients permanently
- Continuous cardiac monitoring during infusion, especially first dose
Anthracyclines (Doxorubicin) 3, 1:
- Baseline echocardiography also required in patients with known cardiac disease
- ECG primarily monitors for acute arrhythmias during infusion (rarely significant)
- Long-term cardiomyopathy risk is dose-dependent (limit cumulative doses)
When ECG Not Routinely Required 4:
Low-risk scenario example: Healthy patient starting low-risk SSRI (sertraline) with no other QT-prolonging factors - routine ECG monitoring rarely needed. However, clinical judgment and risk stratification always apply.
Common Pitfalls to Avoid
- Failing to check drug interactions before adding second QT-prolonging agent - consider alternative antibiotics (penicillins, cephalosporins) instead of fluoroquinolones or macrolides 4
- Not correcting electrolytes before rechecking QTc - hypokalemia and hypomagnesemia are the most modifiable risk factors
- Using inconsistent QTc measurement methods - use same lead and correction formula (Bazett's or Fridericia's) for serial measurements 1, 2, 1
- Transporting unstable patients - if QTc >500 ms or ≥60 ms increase, patient should remain in monitored unit with defibrillator immediately available 5
- Forgetting that cancer patients have competing mortality risks - if no alternative therapy exists and cancer is life-threatening, may proceed with intensified ECG monitoring despite QT prolongation 1, 2, 1